Consensus estimates for Rocket Pharmaceuticals place Q2 2026 revenue at $0.22 million and EPS at $0.28, with the stock currently trading near $3.41 against an average analyst price target of $9.39.
Investors are primarily focused on the clinical status update for RP-A501, the company's gene therapy for Danon disease, which recently reinitiated dosing in a pivotal Phase 2 study following the lifting of a clinical hold.
The expected swing to a quarterly profit is largely driven by the $180 million monetization of a Priority Review Voucher received after the recent FDA approval of KRESLADI. This significant influx of non-dilutive capital has bolstered the balance sheet, extending the company’s projected operational runway into the second quarter of 2028.